Melatonin modulates DNA damage and repair in colonocytes of subjects with ulcerative colitis

Gastroenterologia Polska

Volumn 18, Issue 2, 2011, Pages 67-71

  Chojnacki, Jan ^a   Wiśniewska Jarosińska, Maria ^a   Śliwiński, Tomasz ^b   Błasiak, Janusz ^b   Chojnacki, Cezary ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

Author keywords

Colonocytes; DNA damage; DNA repair; Melatonin; Ulcerative colitis

Indexed keywords

DNA; HYDROGEN PEROXIDE; MELATONIN;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; COLON BIOPSY; COLON MUCOSA; COMET ASSAY; DNA DAMAGE; DNA REPAIR; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE CELL; MALE; OXIDATIVE STRESS; PROTECTION; ULCERATIVE COLITIS;

EID: 84855223444     PISSN: 12329886     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Russel M.G.V.M., Stockbrugger R.W.: Epidemiology of inflammatory bowel disease: an update. Scand. J. Gastroenterol., 1996, 31, 417-427. (Pubitemid 26153633)
2. Head K.A., Jurenka J.S.: Inflammatory bowel disease part I: ulcerative colitis - pathophysiology and conventional and alternative treatment options. Altern. Med. Rev., 2003, 8, 247-283. (Pubitemid 37099887)
3. Levenstein S., Prantera C.,Varvo V., Scribano M.L., Berto E., Andreoli A., Luzi C.: Psychological stress and disease activity in ulcerative colitis: a multidimensional cross-sectional study. Am. J. Gastroenterol., 1994, 89, 1219-1225. (Pubitemid 24245799)
4. Ames B.N., Shigenaga M.K., Hagen T.M.: Oxidants, antioxidants, and the degenerative diseases of aging. Proc. Natl. Acad. Sci. U. S. A., 1993, 90, 7915-7922. (Pubitemid 23260825)
5. Buffinton G.D., Doe W.F.: Depleted mucosal antioxidant defences in inflammatory bowel disease. Free Rad. Biol. Med., 1995, 19, 911-918.
6. Lih-Brody L., Powell S.R., Collier K.P., Reddy G.M., Cerchia R., Kahn E., Weissman G.S., Katz S., Floyd R.A., McKinley M.J., Fisher S.E., Mullin G.E.: Increased oxidative stress and decreased antioxidant defences in mucosa of inflammatory bowel disease. Dig. Dis. Sci., 1996, 41, 2078-2086. (Pubitemid 26366811)
7. Holmes E.W., Yong S.L., Eiznhamer D., Keshavarzian A.: Glutathione content of colonic mucosa: evidence for oxidative damage in active ulcerative colitis. Dig. Dis. Sci., 1998, 43, 1088-1095. (Pubitemid 28211471)
8. Williams J.G., Hughes L.E., Hallett M.B.: Toxic oxygen metabolite production by circulating phagocytic cells in inflammatory bowel disease. Gut, 1990, 31, 187-193. (Pubitemid 20092154)
9. Simmonds N.J., Allen R.E., Stevens T.R., Van Someren R.N., Blake D.R., Rampton D.S.: Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology, 1992, 103, 186-196.
10. Dull B.J., Salata K., Van Langenhove A., Goldman P.: 5-Aminosalicylate: oxidation by activated leukocytes and protection of cultured cells from oxidative damage. Biochem. Pharmacol., 1987, 36, 2467-2472. (Pubitemid 17096920)
11. Craven P.A., Pfanstiel J., Saito R., DeRubertis F.R.: Actions of sulphasalazine and 5-aminosalicylic acid as reactive oxygen scavengers in the suppression of bile acid-inducedincreases in colonic epithelial cell loss and proliferative activity. Gastroenterology, 1987, 92, 1998-2008. (Pubitemid 17072252)
12. Gionchetti P., Guarnieri C., Campieri M., Belluzzi A., Brignola C., Iannone P., Miglioli M., Barbara L.: Scavenger effect of sulfasalazine, 5-aminosalicylic acid and olsalazine on superoxide radical generation. Dig. Dis. Sci., 1991, 36, 174-178.
13. Yamada T., Volkmer C., Grisham M.B.: Antioxidant properties of 5-ASA: potential mechanism for its anti-inflammatory activity. Can. J. Gastroenterol., 1990, 4, 295-302.
14. Balkwill F., Mantovani A.: Inflammation and cancer: back to Virchow? Lancet, 2001, 357, 539-545. (Pubitemid 32173595)
15. Coussens L.M., Werb Z.: Inflammation and cancer. Nature, 2002, 420, 860-867. (Pubitemid 36019639)
16. Coleman N.S., Foley S., Dunlop S.P., Wheatcroft J., Blackshaw E., Perkins A.C., Singh G., Marsden C.A., Holmes G.K., Spiller R.C.: Abnormalities of serotonin metabolism and their relation to symptoms in untreated celiac disease. Clin. Gastroenterol. Hepatol., 2006, 4, 874-881. (Pubitemid 43994540)
17. Spiller R.C., Jenkins D., Thornley J.P., Hebden J.M., Wright T., Skinner M., Neal K.R.: Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut, 2000, 47, 804-811.
18. Bolandparvaz S., Vasei M., Owji A.A., Ata-Ee N., Amin A., Daneshbod Y., Hosseini S.V.: Urinary 5-hydroxy indole acetic acid as a test for early diagnosis of acute appendicitis. Clin. Biochem., 2004, 37, 985-989. (Pubitemid 39388660)
19. Coates M.D., Mahoney C.R., Linden D.R., Sampson J.E., Chen J., Blaszyk H., Crowell M.D., Sharkey K.A., Gershon M.D., Mawe G.M., Moses P.L.: Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology, 2004, 126, 1657-1664. (Pubitemid 38736329)
20. Ghia J.E., Li N., Wang H., Collins M., Deng Y., El-Sharkawy R.T., Côté F., Mallet J., Khan W.I.: Serotonin has a key role in pathogenesis of experimental colitis. Gastroenterology, 2009, 137, 1649-1660.
21. Khan W.I., Gia J.E.: Gut hormones: emerging role in immune activation and inflammation. Clin. Exp. Immunol., 2010, 161, 19-27.
22. Konturek S.J., Konturek P.C., Brzozowska I., Pawlik M., Śliwowski Z., Cześnikiewicz-Guzik M., Kwiecień S., Brzozowski T., Bubenik G.A., Pawlik W.W.: Localization and biological activities of melatonin in intact and diseased gastrointestinal tract (GIT). J. Physiol. Pharmacol., 2007, 58, 381-405. (Pubitemid 47523085)
23. Reiter R.J., Tan D.X., Mayo J.C., Sainz R.M., Leon J., Bandyopadhyay D.: Neurally-mediated and neurally-independent beneficial actions of melatonin in the gastrointestinal tract. J. Physiol. Pharmacol., 2003, 54, Suppl. 4, 113-125.
24. D'Inca R., Cardin R., Benazzato L., Angriman I., Martines D., Sturniolo G.C.: Oxidative DNA damage in the mucosa of ulcerative colitis increases with disease duration and dysplasia. Inflamm. Bowel Dis., 2004, 10, 23-27. (Pubitemid 38072441)
25. Truelove S.C., Witts L.J.: Cortisone in ulcerative colitis; final report on a therapeutic trial. Br. Med. J., 1955, 4947, 1041-1048.
26. Klaude M., Eriksson S., Nygren J., Ahnström G.: The comet assay: mechanisms and technical considerations. Mutat. Res., 1996, 363, 89-96. (Pubitemid 26225011)
27. Levenstein S., Prantera C., Varvo V., Scribano M.L., Andreoli A., Luzi C., Arcà M., Berto E., Milite G., Marcheggiano A.: Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am. J. Gastroenterol., 2000, 95, 1213-1220. (Pubitemid 30263515)
28. Sturniolo G.C., Mestriner C., Lecis P.E., D'Odorico A., Venturi C., Irato P., Cecchetto A., Tropea A., Longo G., D'Inca R.: Altered plasma and mucosal concentrations of trace elements and antioxidants in active ulcerative colitis. Scand. J. Gastroenterol., 1998, 33, 644-649. (Pubitemid 28300247)
29. Aslan M., Nazligu Y., Bolukbas C., Bolukbas F.F., Horoz M., Dulger A.C., Erdur F.M., Celik H., Kocyigit A.: Peripheral lymphocyte DNA damage and oxidative stress in patients with ulcerative colitis. Pol. Arch. Med. Wewn., 2011, Arch. Med. Wewn., 2011, 121, 223-229.
30. Croog V.J., Ullman T.A., Itzkowitz S.H.: Chemoprevention of colorectal cancer in ulcerative colitis. Int. J. Colorectal Dis., 2003, 18, 392-400. (Pubitemid 37062729)
31. Brömme H.J., Mörke W., Peschke E.: Transformation of barbituric acid into alloxan by hydroxyl radicals: interaction with melatonin and with other hydroxyl radical scavengers. J. Pineal Res., 2002, 33, 239-247. (Pubitemid 35252996)
32. López-Burillo S., Tan D.X., Mayo J.C., Sainz R.M., Manchester L.C., Reiter R.J.: Melatonin, xanthurenic acid, resveratrol, EGCG, vitamin C and alpha-lipoic acid differentially reduce oxidative DNA damage induced by Fenton reagents: a study of their individual and synergistic actions. J. Pineal Res., 2003, 34, 269-277. (Pubitemid 36469773)
33. Rodriguez C., Mayo J.C., Sainz R.M., Antolín I., Herrera F., Martín V., Reiter R.J.: Regulation of antioxidant enzymes: a significant role for melatonin. J. Pineal Res., 2004, 36, 1-9. (Pubitemid 38130283)
34. Tomás-Zapico C., Coto-Montes A.: A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J. Pineal Res., 2005, 39, 99-104. (Pubitemid 41140746)
35. Lee P.P., Pang S.F.: Melatonin and its receptors in the gastrointestinal tract. Biol. Signals, 1993, 2, 181-193. (Pubitemid 24084998)
36. Bubenik G.A., Pang S.F.: The role of serotonin and melatonin in gastrointestinal physiology: ontogeny, regulation of food intake, and mutual serotonin-melatonin feedback. J. Pineal Res., 1994, 16, 91-99. (Pubitemid 2083512)
37. Song G.H., Leng P.H., Gwee K.A., Moochhala S.M., Ho K.Y.: Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut, 2005, 54, 1402-1407. (Pubitemid 41375196)
38. Lu W.Z., Gwee K.A., Moochhalla S., Ho K.Y.: Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study. Aliment. Pharmacol. Ther., 2005, 22, 927-934. (Pubitemid 41634873)